Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for Mytesi ® ...
Business Wire

Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure ...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present new findings at the American College of Gastroenterology (ACG) 2024 Annual ...

Article About Groundbreaking Results from Study of Jaguar Health’s Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication

Crofelemer has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency for SBS and MVID. In October 2025, as announced, the company ...
The Journal News

Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer

Enrollment in company’s first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached ...

Jaguar Health, Inc.: Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for Mytesi and Canalevia-CA1, which has the potential to provide Jaguar up to an additi ...